A recent meta-analysis designed to ascertain AE prevalence in DBS concluded that the true prevalence of AEs could not be accurately determined because there was an absence of standardized reporting. 18 In this paper, we describe our prospective and standardized method of recording AEs, that is equivalent to AE recording in pharmaceutical clinical trials. We summarized all recorded AEs intraoperatively and up to 180 days postoperatively, and we correlated these values with QOL and other clinical outcome measures.
Methods

Patient Population
All patients who underwent DBS operations at the University of Florida Movement Disorders Center between June 2002 and April 2008 for PD, ET, dystonia, other tremor (poststroke, multiple sclerosis, posttraumatic), and OCD were included in the study. Institutional review board approval and informed consent were obtained for all patients who agreed to have their data prospectively entered into the database. All diagnoses were given by fellowshiptrained movement disorders neurologists using strict criteria for PD, ET, dystonia, and other tremor conditions. All patients underwent a multidisciplinary screening (neurology, neurosurgery, psychology, and psychiatry) prior to surgery. Patients who originally underwent operations at outside institutions were excluded from the study.
Surgical Method
To establish a coordinate system for DBS targeting, a Cosman-Roberts-Wells head ring (Radionics) was affixed to the awake patient and a stereotactic head CT scan was then acquired and fused to a 1.5-or 3.0-T MR image obtained on the day prior to surgery. Target coordinates were obtained after the images were fused. The CosmanRoberts-Wells frame was set to the target coordinates and targeting accuracy was verified on a phantom ring. Multiple pass microelectrode mapping was used to verify the target position. A Medtronic DBS lead was implanted in each brain side that was operated on, and macrostimulation was performed following microelectrode recording to assess thresholds for benefits and side effects, as well as to assess programmability. Lead locations were adjusted if thresholds were discovered to be suboptimal. The lead was secured with a Navigus cap. All lead locations were assessed 1-month postoperatively by CT-MR fusion at which time pulse generators were also implanted. In this study, all AEs and outcome scale scores were recorded within 180 days after DBS. These AEs were summarized and analyzed. The basic unit of analysis was each intracranial lead placement, rather than using each patient. Operations occurring > 180 days apart were analyzed separately. Lead placements within 180 days in the same patient were categorized as a bilateral procedure.
Recording AEs
The latest version of the form used to record AEs is presented in Fig. 1 . It has been revised twice over the last 6 years: once to include 2 additional descriptive categories, and once to combine AEs due to chronic stimulation, which had previously appeared on a separate programming form. This capture system combines AEs that are expected to arise from both surgery and stimulation, as both may result in DBS-related issues. The AEs are categorized so that multiple users can more easily locate the correct AE that will accurately describe their patient. The qualifiers on the forms provide valuable categorizations that can make later analysis more meaningful. For elaboration, a box for written comments at the bottom of the form is also included. A brief sentence not only validates the AE and its descriptive fields, but also allows for a description of interventions and outcomes.
Relevant Outcome Measures
Change in QOL was obtained by comparing the preoperative to the postoperative scores at 6 months on the PDQ-39 (for patients with PD) or MOS-36 (for patients with tremor and dystonia) scales. The extent of an improvement or worsening was determined by standardizing change scores as compared with the preoperative scores. The entire cohort was then categorized as having > 25% improvement, ≤ 25% improvement, ≤ 25% worsening, or > 25% worsening. Change in motor function was obtained by comparing the UPDRS score (for patients with PD), TRS score (for ET and other tremor conditions), and DRS score (for patients with dystonia) preoperatively when the patient was not taking medications, and postoperatively at 6 months off medication and on stimulation. The PGIS scores for all patients were also queried at the 6-month postoperative interval. The PGIS is a 7-point scale in which the patient determines if he or she is very much improved, much improved, minimally improved, unchanged, minimally worse, much worse, or very much worse at the time of evaluation compared with the pre-DBS state, both in terms of the patient's general condition (General PGIS score), and separately for the main symptom that the patient wanted DBS to improve (SymptomSpecific PGIS score). These outcome measures are then compared and correlated with the presence, frequency, severity, and duration of AEs.
All collected data were analyzed using the SAS statistical program version 9.1. For comparisons in changes in QOL (PDQ-39 or MOS-36 score), motor function (UPDRS, TRS, and DRS scores), and PGIS scores between operations associated with and without AEs, 2-sample t-tests were employed. The association between QOL change category and AE severity was assessed using the Mantel-Haenszel test with modified ridit scores. Statistical significance of all tests was evaluated at the significance level of 0.05.
Results
Two hundred seventy DBS procedures were performed in 198 patients ( Table 1 ). The mean age of the patients was 57.2 ± 15.8 years (range 8-89 years). One hundred thirty-three (67.2%) of the patients were male. Among that cohort of patients, 26 had dystonia, 43 had ET, 113 had PD, 6 had OCD, and 10 had other causes of tremor (multiple sclerosis, posttraumatic, poststroke). The DBS leads were implanted on the left hemisphere in 133 procedures (49.3%), on the right in 88 (32.6%), and bilaterally in 49 (18.1%).
A total of 300 AEs were recorded in 146 of the 270 procedures (54.1%; Table 3 . There was no significant difference in the standardized QOL changes from before to after operations between patients who did not experience an AE versus those who experienced any AE (p = 0.22). Categorization on standardized QOL changes resulted in 58 operations (25.6%) with > 25% improvement in QOL, 80 operations (35.4%) with ≤ 25% improvement in QOL, 65 operations (28.8%) with ≤ 25% worsening in QOL, and 23 operations (10.2%) with > 25% worsening in QOL. The association between the QOL change category and the severity of complication was not significant. There was no significant difference in the mean General PGIS score between patients who did not experience an AE compared with those who experienced any AE (1.94 vs 2.1; p = 0.34) as well as the mean Symptom-Specific PGIS score (1.9 vs 2.04; p = 0.40).
Motor function outcomes did not vary between patients with and without AEs. For patients with PD with and without AEs, there was no significant difference in preoperative off-medicine UPDRS score and postoperative Months 4-6 on-medicine/on-stimulation changes (p = 0.59; Table 4 ). Similarly for patients with tremor there were no differences in TRS changes between those with and without AEs for motor function (p = 0.58) or for activities of daily living (p = 0.15) as measured by the TRS. Patients with dystonia with and without AEs showed no differences in the UDRS score (p = 0.35).
Discussion
The AE rates reported at our institution were at the high end of the spectrum. Within the first 180 days, more than 54% of the procedures involved an AE, and one-third (30.4%) of those were severe, based on a rigid definition adapted from pharmacological trials. With chronic stimulation and multiple implantable pulse generator changes, an even greater percentage of patients will likely have some type of AE during the course of treatment. These data, however, should not be discouraging, because patients with and without AEs appear to both perform well on standardized outcome measures and on the PGIS. The presence of mild, moderate, severe, or any AEs did not significantly affect patients in terms of their preoperative and 180-day postoperative motor function scale and QOL scale score changes, or of their own subjective assessment of their state after surgery (PGIS). Although this may be expected for those with mild or moderate AEs, it is somewhat surprising to find this remains true even for those who experienced severe AEs (an AE resulting in a lifethreatening complication, or a new or greater than 3-day hospitalization). This finding may have been a result of the inclusive definition for a severe AE; for example, if the patient stayed in the hospital for more than 3 days due to social reasons, or was subsequently readmitted to the hospital for observation over a concern that was either unrelated to DBS or was not clinically significant, this would have been classified as a severe AE.
This study underscores some important issues facing DBS concerning AEs and AE reporting. It is clear that if prospectively acquired and recorded regardless of their perceived relationship to surgery or stimulation, the AE logs for this therapy should approximate, if not naturally exceed, the long lists of AEs reported for even the most benign pharmacological agents. The pre-and postmarketing reports of any pharmaceutical product have long adopted a standardized approach to reporting all AEs and have considered this the most important aspect of new product development, allowing the clinician a better comparison of the safety profile of each drug in its class or of each indication. Deep brain stimulation will need to move toward standardization of an approach for reporting AEs. Whereas it has already been established that DBS is an efficacious treatment for many disorders, 3, 4, 16, 17 its risk-benefit ratio is in large part contributed to by the frequency and severity of AEs. Only standardized and prospective recording of AEs will allow the proper estimation of margins of therapeutic benefit and tolerability, the identification of the most at-risk surgical populations, and the generalizability of the benefit derived from the procedure between surgical centers. So as not to discourage other centers from recording prospectively and classifying systematically all AEs, we looked at the QOL and other relevant outcome measures to the frequency and severity of AEs and found no difference in QOL among patients with AEs versus those without AEs. This finding is particularly important as general outcome scores from this study and from others published in the literature continue to reflect satisfaction with the results of DBS regardless of the occurrence of AEs. Since the late 1980s, DBS has evolved from an experimental procedure to an established treatment modality for many diagnoses worldwide. 1, 6, 7, 12 Current research, especially in the field of neuropsychiatric disorders, will likely lead to a vast increase in the patient population for whom DBS will become available. 9, 13, 17 Because the procedure is elective, it will be important to better establish the risk-benefit ratio as well as the short-and long-term issues associated with the procedure.
Conclusions
The use of a standardized, prospective recording system for AEs reduces the bias introduced by memory, inter-and intraprovider variability, and unfocused medical record keeping. This type of system results in the reporting of higher but more accurate AE rates. If adopted by centers worldwide, such a system as reported here will allow for the more uniform comparison of AE rates between institutions. This new data set has the potential to compare AEs among differing philosophies and techniques from different institutions, uncover subtle trends that would otherwise go undetected, assess short-and 
